Cerus Co. (NASDAQ:CERS) insider Richard J. Benjamin sold 9,890 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $5.96, for a total value of $58,944.40. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $17,880. The sale was disclosed in a filing with the SEC, which is available through this link.
NASDAQ CERS traded up $0.11 on Friday, reaching $6.28. The stock had a trading volume of 503,158 shares, compared to its average volume of 744,396. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.79 and a quick ratio of 2.53. Cerus Co. has a 1-year low of $4.70 and a 1-year high of $8.05. The firm has a market cap of $855.96 million, a price-to-earnings ratio of -14.26 and a beta of 1.44.
Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $16.50 million during the quarter, compared to analyst estimates of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) earnings per share. On average, equities analysts anticipate that Cerus Co. will post -0.42 earnings per share for the current fiscal year.
A number of research analysts have commented on the company. BidaskClub lowered Cerus from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Zacks Investment Research lowered Cerus from a “buy” rating to a “hold” rating in a report on Monday, March 4th. ValuEngine raised Cerus from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Cerus in a report on Tuesday, December 18th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Cerus has a consensus rating of “Buy” and a consensus price target of $8.50.
Large investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in shares of Cerus during the 4th quarter valued at $55,000. Raymond James Trust N.A. bought a new stake in shares of Cerus during the 4th quarter valued at $71,000. Mackenzie Financial Corp bought a new stake in shares of Cerus during the 3rd quarter valued at $119,000. Shufro Rose & Co. LLC lifted its position in shares of Cerus by 13.3% during the 4th quarter. Shufro Rose & Co. LLC now owns 17,000 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 2,000 shares during the period. Finally, Amalgamated Bank bought a new stake in shares of Cerus during the 4th quarter valued at $99,000. Hedge funds and other institutional investors own 65.15% of the company’s stock.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Story: What factors cause inflation to rise?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.